Correlation between the progression of left ventricular hypertrophy and neuroendocrine factors in patients with refractory hypertension

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100047964

Enrollment

Unknown

Registered

2021-06-28

Start date

2021-07-01

Completion date

Unknown

Last updated

2022-03-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractory hypertension

Interventions

case series:antihypertensive therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: According to the latest Chinese guidelines for the prevention and treatment of hypertension, patients with refractory hypertension (RH) who were admitted to the outpatient and inpatient wards of the Department of Cardiology of the University of Hong Kong Shenzhen Hospital were screened.

Exclusion criteria

Exclusion criteria: 1. Patients with secondary hypertension and tumors; 2. Patients with rheumatic immune diseases, acute coronary syndrome, acute stroke; 3. Patients with severe renal insufficiency (eGFR<30ml/min/1.73m^2) and severe infection.

Design outcomes

Primary

Measure	Time frame
Blood pressure, heart rate, major cardiovascular adverse events;	—

Countries

China

Contacts

Public ContactCao Gaozhen

The University of Hong Kong - Shenzhen Hospital

caogz@hku-szh.org+86 18925232825

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026